Grifols SA ( (GRFS) ) has released its Q4 earnings. Here is a breakdown of the information Grifols SA presented to its investors.
Grifols SA is a global healthcare company based in Barcelona, specializing in plasma-derived medicines and transfusion medicine, with a strong presence in over 110 countries.
Grifols has reported a robust financial performance for 2024, surpassing its revenue and free cash flow guidance. The company achieved record results, driven by its Biopharma business and strategic initiatives, positioning itself for sustainable growth.
Key financial highlights include a 10.3% increase in full-year revenue to EUR 7,212 million, with a notable 13.6% growth in the fourth quarter. Adjusted EBITDA rose by 19% in Q4, reaching EUR 526 million, and the full-year adjusted EBITDA was EUR 1,779 million. Net profit saw a significant improvement, almost tripling to EUR 157 million for the year. The company also made progress in deleveraging, reducing its leverage ratio to 4.6x and enhancing its liquidity position to EUR 1.9 billion.
Grifols’ Biopharma segment continues to be a key growth driver, with a 15.1% increase in the fourth quarter and a 11.3% rise for the full year. The immunoglobulin franchise showed strong growth, with SCIG experiencing a 55.5% increase. The company also achieved all its innovation milestones for 2024, including regulatory submissions for Fibrinogen in the EU and U.S.
Looking ahead, Grifols is focused on maintaining its growth trajectory through continued innovation and strategic partnerships. The management remains optimistic about the company’s ability to achieve sustainable, profitable growth in 2025 and beyond.